Celcuity (CELC) Research & Development (2016 - 2026)
Celcuity's Research & Development was $31.08 million in Q2 2026, down 14.7% from $36.42 million a year earlier.
Powered by 
Analysis
Celcuity (CELC) Research & Development (2016 - 2026) Analysis & Trends
On a trailing twelve-month basis, Celcuity's Research & Development was $140.04 million through Jun 30, 2026, up 8.0% year-over-year; for FY2025, it came in at $145 million, up 39.2% from FY2024.
- Research & Development has now increased for six consecutive years, with a five-year compound annual growth rate of 80.0% (FY2020 to FY2025).
- In earlier years, Research & Development was $104.2 million in FY2024 (+72.0%), $60.59 million in FY2023 (+71.7%), $35.29 million in FY2022 (+37.0%) and $25.76 million in FY2021 (+235.2%).
- The Q2 2026 figure marks the lowest quarterly Research & Development since Q3 2024.
- Compared with a year earlier, Research & Development was higher in six of the last seven quarters, with growth averaging 40.7%.
- The best year-over-year quarter for Research & Development over five years was Q1 2022 (growth of 199.4%); the worst was Q2 2022 (a decline of 36.0%).
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | R&D (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 655.56 Bn | 574.09 Bn | 17.26 Bn | 3.65 Bn |
| 2 | AbbVie | 470.94 Bn | 444.10 Bn | 12.70 Bn | 2.34 Bn |
| 3 | Merck | 367.14 Bn | 321.57 Bn | 12.21 Bn | 9.74 Bn |
| 4 | Novartis Ag | 280.33 Bn | 236.20 Bn | 11.24 Bn | -2.85 Bn |
| 5 | Astrazeneca | 257.78 Bn | 231.34 Bn | 12.86 Bn | -4.05 Bn |
| 6 | Amgen | 226.04 Bn | 181.44 Bn | 7.24 Bn | 1.87 Bn |
| 7 | Gilead Sciences | 188.89 Bn | 163.01 Bn | 6.22 Bn | 1.76 Bn |
| 8 | Pfizer | 163.75 Bn | 110.70 Bn | 10.94 Bn | 2.81 Bn |
| 9 | Vertex Pharmaceuticals | 133.68 Bn | 105.69 Bn | 2.84 Bn | 993.80 Mn |
| 10 | Celcuity | 3.90 Bn | 3.90 Bn | - | 31.08 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 31.08 Mn |
| Dec 31, 2025 | 37.64 Mn |
| Sep 30, 2025 | 34.92 Mn |
| Jun 30, 2025 | 36.42 Mn |
| Mar 31, 2025 | 32.23 Mn |
| Dec 31, 2024 | 33.47 Mn |
| Sep 30, 2024 | 27.59 Mn |
| Jun 30, 2024 | 22.50 Mn |
| Mar 31, 2024 | 20.65 Mn |
| Dec 31, 2023 | 18.08 Mn |
| Sep 30, 2023 | 17.49 Mn |
| Jun 30, 2023 | 13.75 Mn |
| Mar 31, 2023 | 11.28 Mn |
| Dec 31, 2022 | 10.60 Mn |
| Sep 30, 2022 | 9.62 Mn |
| Jun 30, 2022 | 8.37 Mn |
| Mar 31, 2022 | 6.70 Mn |
| Dec 31, 2021 | 5.49 Mn |
| Sep 30, 2021 | 4.96 Mn |
| Jun 30, 2021 | 13.07 Mn |
API Access
Celcuity Research & Development API
Pull this series into your own models, spreadsheets and apps with the Business Quant
Historical Metrics API. The request below matches the chart above — change the
frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.
https://data.businessquant.com/historic?slug=research-and-development&ticker=CELC&period=max&api_key=YOUR_API_KEYimport requests
url = "https://data.businessquant.com/historic"
params = {"slug": "research-and-development", "ticker": "CELC", "period": "max", "api_key": "YOUR_API_KEY"}
data = requests.get(url, params=params).json()const res = await fetch("https://data.businessquant.com/historic?slug=research-and-development&ticker=CELC&period=max&api_key=YOUR_API_KEY");
const data = await res.json();